Study on cytogenetic changes with relation to FAB classification in 397 patients with acute leukemias.
- Author:
Fei-Fei HUO
1
;
Xin LIU
;
Zi-Min SUN
;
Wei-Bo ZHU
;
Chang-Cheng ZHENG
;
Jian WANG
;
Zhi-Wei WU
Author Information
1. Department of Hematology, Anhui Medical University, Hefei 230001, Anhui Province, China.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Child;
Chromosome Aberrations;
Female;
Humans;
Karyotype;
Karyotyping;
Leukemia;
genetics;
Male;
Middle Aged;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(1):6-10
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of study was to investigate the cytogenetic abnormality of acute leukemias (AL), to analyze the relationship in the chromosomal abnormality and the AL FAB types, and to explore the impact of the chromosomal abnormalities on the prognostic factors of AL. The chromosome karyotypes of 397 patients with AL were analyzed by means of bone marrow short-term culture and G banding technique. The results showed that in 319 out of 397 patients, the chromosome karyotypes could be analyzed, and the chromosomal abnormality occurred in 175 patients (54.9%). In the patients with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML) and acute mixed-lineage leukemia (AMLL), the chromosomal abnormality occurred respectively in 33 of 120 patients (27.5%), 129 of 252 patients (51.2%) and 13 of 25 patients (52.0%). Hyper-diploids, hypo-diploids and diploids occurred in 41 of 175 patients (23.4%), 22 of 175 patients (12.5%), and 112 of 175 patients (64.0%) respectively. In patients with AML the FAB type-associated chromosomal abnormality occurred in 69 of 129 patients (53.5%). It is concluded that chromosomal abnormalities exist in about 55% AL patients. Some special chromosomal abnormalities are cytogenetic characteristics of AL, and obviously correlated with AL FAB types, the combination of chromosomal detection with cytogenetics is useful for the diagnosis of AL, and the evaluation of therapeutic effects and prognosis.
